Grifols SA 2019 IR
The report highlights Grifols' achievements in 2019, showcasing record revenues of EUR 5,099 million and a total socioeconomic impact of EUR 8,500 million. The company made significant progress in its clinical trials, notably presenting positive findings from the AMBAR trial for Alzheimer's disease. Grifols also expanded its global footprint through a strategic alliance with Shanghai RAAS in China and successfully completed a EUR 5,800 million debt refinancing process. On the environmental front, the company established six core commitments for 2030, including a 40% reduction in greenhouse gas emissions and a target to consume 70% of electricity from renewable sources.
Company: Grifols SA
Sector: Manufacturing
Country: Spain
Year: 2019
Type: IR
Pages: 211
Grifols SA
The report highlights Grifols' achievements in 2019, showcasing record revenues of EUR 5,099 million and a total socioeconomic impact of EUR 8,500 million. The company made significant progress in its clinical trials, notably presenting positive findings from the AMBAR trial for Alzheimer's disease. Grifols also expanded its global footprint through a strategic alliance with Shanghai RAAS in China and successfully completed a EUR 5,800 million debt refinancing process. On the environmental front, the company established six core commitments for 2030, including a 40% reduction in greenhouse gas emissions and a target to consume 70% of electricity from renewable sources.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Water Consumption
Total Waste
Women on Board
Women in Management
Employees